Thus, targeting metabolic reprogramming, particularly fatty acid synthase (FASN) inhibition, in combination with standard HER2-targeted therapies represents a promising approach for overcoming resistance to anti-HER2 therapy in HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast cancer.